MedTech Dive June 26, 2023
Nick Paul Taylor

Dive Brief:

  • Dexcom next year will introduce a continuous glucose monitor aimed at the 25 million non-insulin-using Americans with Type 2 diabetes.
  • The CGM, which is based on the Dexcom G7, will last for 15 days, include a cash-pay option and come with software designed for the needs of people who are yet to require insulin.
  • Dexcom’s analysis shows those patients want help understanding the effect of lifestyle on blood glucose and staying off insulin, leading the company to develop a revised set of features for the new device.

Dive Insight:

While about half of people with Type 1 diabetes and Type 2 patients on intensive insulin therapy use a CGM, according to Dexcom, they make up...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Patient / Consumer, Provider, Technology, Wearables
Related Articles:
Oura Ring Is ‘Like An Apple Product’ And Could Take Key Health Metric Mainstream
Wearable ultrasound sensor revolutionizes continuous blood pressure monitoring
Wearable Health Tech: Innovations and Impacts on Chronic Disease Management
Driving Urgent Change To Optimize The Patient Experience
Sibionics Blood Glucose Sensor: Review

Share This Article